Merck & Co., Inc. (FRA:6MK)
68.10
-0.60 (-0.87%)
At close: Jun 26, 2025, 10:00 PM CET
Merck & Co. Revenue
Merck & Co. had revenue of $15.53B USD in the quarter ending March 31, 2025, a decrease of -1.56%. This brings the company's revenue in the last twelve months to $63.92B, up 4.10% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$63.92B
Revenue Growth
+4.10%
P/S Ratio
2.92
Revenue / Employee
$852.29K
Employees
75,000
Market Cap
172.86B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.15B |
Siemens Aktiengesellschaft | 77.82B |
Deutsche Telekom AG | 120.25B |
Allianz SE | 109.03B |
Rheinmetall AG | 10.48B |
Siemens Energy AG | 37.44B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
Siemens Healthineers AG | 23.14B |
Merck & Co. News
- 2 days ago - US stocks threatens to close at record levels but closes just off record levels - Forexlive
- 2 days ago - Merck's RSV shot for infants gets key approval despite RFK Jr.'s panel shakeup - Fast Company
- 2 days ago - Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise - Benzinga
- 2 days ago - ACIP Recommends Use of Merck’s ENFLONSIA (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season - Wallstreet:Online
- 2 days ago - ACIP Recommends Use of Merck's ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season - Business Wire
- 2 days ago - RFK Jr’s vaccine panel recommends new RSV treatment for infants - The Guardian
- 2 days ago - RFK Jr.'s CDC vaccine panel backs Merck RSV shot for infants - CNBC
- 2 days ago - Merck wins CDC AdCom backing for RSV shot - Seeking Alpha